Key result
Metabolic syndrome linked to ~32% faster aortic stenosis progression, especially in younger patients.
Why the study?
Statins have failed to slow aortic stenosis progression in randomized trials, but retrospective studies reported an association between metabolic syndrome and faster progression, requiring prospective evaluation.
Does metabolic syndrome accelerate the progression of aortic stenosis?
Cohort (n=243)
Does metabolic syndrome accelerate the progression of aortic stenosis?
Metabolic syndrome is an independent predictor of faster aortic stenosis progression, particularly in younger patients.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; leaves open whether treating metabolic syndrome slows AS progression in younger patients.
OBJECTIVES: The aims of this study were to examine prospectively the relationship between metabolic syndrome (MetS) and aortic stenosis (AS) progression and to evaluate the effect of age and statin therapy on AS progression in patients with or without MetS. BACKGROUND: Despite the clear benefits of statin therapy in primary and secondary coronary heart disease prevention, several recent randomized trials have failed to demonstrate any significant effect of this class of drugs on the progression of AS. Previous retrospective studies have reported an association between MetS and faster AS progression. METHODS: This predefined substudy included 243 of the 269 patients enrolled in the ASTRONOMER (AS Progression Observation: Measuring Effects of Rosuvastatin) trial. Follow-up was 3.4 ± 1.3 years. AS progression rate was measured by calculating the annualized increase in peak aortic jet velocity measured by Doppler echocardiography. RESULTS: Patients with MetS (27%) had faster stenosis progression (+0.25 ± 0.21 m/s/year vs. +0.19 ± 0.19 m/s/year, p = 0.03). Predictors of faster AS progression in multivariate analysis were older age (p = 0.01), higher degree of valve calcification (p = 0.01), higher peak aortic jet velocity at baseline (p = 0.007), and MetS (p = 0.005). Impact of MetS on AS progression was most significant in younger (< 57 years) patients (MetS: +0.24 ± 0.19 m/s/year vs. no MetS: +0.13 ± 0.18 m/s/year, p = 0.008) and among patients receiving statin therapy (+0.27 ± 0.23 m/s/year vs. +0.19 ± 0.18 m/s/year, p = 0.045). In multivariate analysis, the MetS-age interaction was significant (p = 0.01), but the MetS-statin use interaction was not. CONCLUSIONS: MetS was found to be a powerful and independent predictor of faster AS progression, with more pronounced impact in younger patients. These findings emphasize the importance of routinely identifying and treating MetS in AS patients. The apparent faster stenosis progression in the subset of normocholesterolemic patients with MetS receiving the statin will need to be confirmed by future studies.
No takes yet. Share an insight, caveat, or question.
Capoulade et al. (2012) conducted a cohort in Aortic stenosis (n=243). Metabolic syndrome vs. No metabolic syndrome was evaluated on Annualized increase in peak aortic jet velocity (p=0.03). Metabolic syndrome was associated with faster aortic stenosis progression compared to patients without it, with a more pronounced impact in younger patients.
Synapse has enriched 10 related papers. Consider them for comparative context: